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Aim
The re-emerging invalidating chikungunya (CHIK) disease
has recently extended to temperate areas. Following the
acute febrile polyarthritis, miscellaneous long-lasting rheu-
matic musculoskeletal disorders (RMSKD) are reported,
consistent with chronic inflammatory rheumatisms (CIR)
notably rheumatoid arthritis (RA). The post CHIK-infec-
tion stage remains a challenge to treat, while the early use
of disease-modifying antirheumatic drugs (DMARDs) is
recommended in RA. After the 2005-2006 CHIK outbreak
in Reunion Island, we retrospectively categorized CHIK-
related RSMKD and analyzed the empirical use of
DMARDs starting with methotrexate (MTX) to treat the
CIR forms.
Materials and methods
We reviewed medical files of patients referred to rheuma-
tologists in Saint Denis between 12/2005-05/2012 for per-
sisting rheumatic disorders (>4 months) after a proven
CHIK infection. We distinguished de novo post-CHIK
RMSKD from exacerbation of pre-existing disorders. CIR
included: 1) RA defined according 2010 ACR/EULAR cri-
teria, 2) spondylarthropathy (SA) defined according ESSG
classification, and 3) undifferentiated polyarthritis (UP)
defined as at least three swelling joints. Response to
MTX was efficacy versus failure (defined as a need for
MTX switch or escalation). Determinants for efficacy
were identified using Fisher exact test.
Results
Among 159 patients included, 122 suffered from de novo
RSMKD with 28 presenting chronic pains and 94 fulfilling
CIR criteria. RA accounted for 40/92 (12 positive for anti-
CCP antibodies); SA for 33/94 (15 with psoriasis); and dis-
tal UP for 21/94. 72 of them (including the 31 CIR with
joint damages) were treated with MTX (40 RA, 26 SA),
reaching efficacy in 54 cases (30 RA, 19 SA, 5 UP) versus
failure in 18 cases (10 RA, 7 SA, 1 UP). No severe side
event was observed. The group efficacy did not differ with
age, sex or type of CIR, but was significantly associated
with the early introduction of MTX within the first year of
CIR progression (p =0,034).
Conclusions
Among the wide spectrum of post CHIK RMSKD, CIR
should benefit from the early use of MTX. DMARD’s effi-
cacy could bring some clues to investigate the underlying
post CHIK-infection disorders.
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